Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UROPET: 68Ga-RM2 PET/CT Versus 68Ga-PSMA-617 PET/CT in Prostate Cancer
NCT03604757Phase 2Completed
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Apr 2018
- Primary completion
- Dec 2019
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of 68Ga-DOTA-Bombesin, 68Ga-PSMA-617 in prostate cancer (PCa), sponsored by Centre Hospitalier Universitaire de Bordeaux. Started Apr 2018; status: completed.
02
Drugs
68Ga-DOTA-Bombesin68Ga-PSMA-617
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03604757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03604757.